Sequenom Eyes $100M in Private Notes Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Monday it plans to offer $100 million in convertible senior notes due 2017.

Proceeds from the private offering will be used to continue commercialization of its MaterniT21 Plus LDT non-invasive aneuploidy test and for general corporate purposes, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.